Product Description
Preclinically, AGX101 has demonstrated a wide therapeutic window – there are no adverse clinical signs in animals at efficacious diseases. Prior clinical studies with a TM4SF1-directed radioimmunoconjugate demonstrated clinically significant responses in 60% of patients in limited dosing with negligible vascular toxicity. Due to TM4SF1’s widespread expression in tumor cells and tumor vasculature, AGX101 has potential to treat most solid cancers. In many cancers, high TM4SF1 expression is associated with early death, suggesting that killing of high-TM4SF1 cancer cells by AGX101 may convert cancers to a less malignant form. (Sourced from: https://angiex.com/pipeline)
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Angiex, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Adenocarcinoma|Pancreatic Cancer|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AGX101-001 | P1 |
Recruiting |
Adenocarcinoma|Pancreatic Cancer|Triple Negative Breast Cancer |
2025-05-01 |